Irkutsk
Ulan-Ude

Blagoveshchensk
Chita
Yakutsk

Birobidzhan
Vladivostok
Khabarovsk

Magadan
Yuzhno-Sakhalinsk

Anadyr
Petropavlovsk-
Kamchatsky
Moscow

This text is translated into Russian by google automatic human level neural machine.
EastRussia is not responsible for any mistakes in the translated text. Sorry for the inconvinience.
Please refer to the text in Russian as a source.

Completed the second phase of research "Sputnik Light"

Completed the second phase of research "Sputnik Light"
Photo: pixabay.com

The second phase of clinical trials of the Sputnik Light coronavirus vaccine has ended in Russia. Currently, the data are sent for expert evaluation.

As the RIA News" with reference to the head of the Ministry of Health of the Russian Federation Mikhail Murashko, permission to conduct the third phase of research was received back in February. It will be completed in January next year.

Sputnik Light is a Gamaleya Center, just like Sputnik V. The "light version" is mainly focused on foreign markets, where there are strong epidemic foci.

The director of the Gamaleya Center, Alexander Gintsburg, said that the vaccination efficiency will be about 85%. It is expected that immunity after vaccination will persist for three to four months.

Sputnik Light vaccination assumes only one injection with the first component of Sputnik V and a shorter period of antibody production.

In Russia, from January 18, began mass vaccination from the coronavirus. Anyone can get vaccinated free of charge and voluntarily. Currently, they are vaccinated against COVID-19 with two vaccines - Sputnik V and EpiVacKorona.

April 23: current information on coronavirus in the Far East
Digest of regional events and latest statistics